1SOBI Stock Overview

A biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. More details

1SOBI fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	3/6
Past Performance	5/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 73% below our estimate of its fair value

Earnings are forecast to grow 16.66% per year

Earnings grew by 84.9% over the past year

Risk Analysis

No risks detected for 1SOBI from our risk checks.

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Swedish Orphan Biovitrum AB (publ) Competitors

Philogen

BIT:PHIL

€878.3m

Recordati Industria Chimica e Farmaceutica

BIT:REC

€10.9b

Exelixis

NasdaqGS:EXEL

US$10.2b

BioMarin Pharmaceutical

NasdaqGS:BMRN

US$11.4b

Price History & Performance

Summary of share price highs, lows and changes for Swedish Orphan Biovitrum
Historical stock prices
Current Share Price	SEK 26.90
52 Week High	SEK 26.10
52 Week Low	SEK 26.10
Beta	0.26
1 Month Change	13.22%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-2.54%

Recent updates

Shareholder Returns

	1SOBI	IT Biotechs	IT Market
7D	-1.3%	-2.1%	2.0%
1Y	n/a	1.9%	11.8%

Return vs Industry: Insufficient data to determine how 1SOBI performed against the Italian Biotechs industry.

Return vs Market: Insufficient data to determine how 1SOBI performed against the Italian Market.

Price Volatility

Is 1SOBI's price volatile compared to industry and market?
1SOBI volatility
1SOBI Average Weekly Movement	5.3%
Biotechs Industry Average Movement	8.4%
Market Average Movement	5.4%
10% most volatile stocks in IT Market	8.7%
10% least volatile stocks in IT Market	3.3%

Stable Share Price: 1SOBI has not had significant price volatility in the past 3 months compared to the Italian market.

Volatility Over Time: Insufficient data to determine 1SOBI's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1939	1,895	Guido Oelkers	www.sobi.com

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma.

Swedish Orphan Biovitrum AB (publ) Fundamentals Summary

How do Swedish Orphan Biovitrum's earnings and revenue compare to its market cap?
1SOBI fundamental statistics
Market cap	€9.34b
Earnings (TTM)	€362.53m
Revenue (TTM)	€2.40b

25.8x

P/E Ratio

3.9x

P/S Ratio

Is 1SOBI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1SOBI income statement (TTM)
Revenue	SEK 26.24b
Cost of Revenue	SEK 5.69b
Gross Profit	SEK 20.54b
Other Expenses	SEK 16.58b
Earnings	SEK 3.96b

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Jul 16, 2025

Earnings per share (EPS)	11.53
Gross Margin	78.30%
Net Profit Margin	15.09%
Debt/Equity Ratio	35.0%

How did 1SOBI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/07 14:55
End of Day Share Price	2025/05/07 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Swedish Orphan Biovitrum AB (publ) is covered by 30 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	ABG Sundal Collier
Xue Chen	Barclays
Rosie Turner	Barclays